The ALDH1B1 Knockout LoVo Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which ALDH1B1 has been functionally disrupted within human LoVo colorectal adenocarcinoma epithelial cells. This polyclonal format provides a heterogeneous pool of cells with loss-of-function mutations, enabling population-level studies of ALDH1B1 function in aldehyde metabolism, retinoic acid biosynthesis, and cancer stem cell biology without the constraints of clonal selection.
The LoVo host cell line was originally established from a metastatic lymph node lesion of a 56-year-old Caucasian male with colorectal adenocarcinoma classified as Dukes?? type C. LoVo cells exhibit an adherent epithelial morphology and are widely employed as a model for invasive colorectal carcinoma and metastatic progression. Their derivation from a metastatic site makes them particularly suitable for investigating the molecular mechanisms underlying colorectal cancer metastasis and therapeutic resistance, thus providing a clinically relevant context for ALDH1B1 knockout studies.
ALDH1B1 functions as a NAD+-dependent aldehyde dehydrogenase forming homotetramers that detoxify aldehydes such as acetaldehyde and 4-hydroxynonenal and contributes to retinoic acid biosynthesis. It is transcriptionally regulated by the CTNNB1/TCF complex, PPARG, and NFE2L2, linking its expression to Wnt, PPAR??, and oxidative stress pathways. Downstream, it modulates retinoic acid signaling through RARA and RXRA, affecting retinoic acid-responsive genes like HOX and CYP26A1, and helps maintain stemness markers CD133 and NANOG.
In LoVo colorectal cancer cells, ALDH1B1 is a cancer stem cell marker, and its knockout likely impairs aldehyde detoxification and retinoic acid production, reducing stemness and increasing sensitivity to oxidative stress and chemotherapy. ALDH1B1 intersects with pathways like glycolysis/gluconeogenesis, fatty acid degradation, and cytochrome P450 xenobiotic metabolism, where it operates alongside ADH1B, ALDH2, CYP2E1, and ALDH1A paralogs. Thus, this polyclonal knockout model enables investigation of ALDH1B1??s role in tumor initiation, metastasis, and drug resistance in a relevant colorectal adenocarcinoma context.
Researchers can employ these cells in cancer stem cell studies, alcohol metabolism research, and drug resistance assays. Key techniques include Aldefluor-based ALDH activity measurement, RT-qPCR and Western blotting for ALDH1B1 and stem markers (CD44, CD133), cell viability assays with ethanol or 5-FU, retinoic acid quantification, and functional tests like colony formation, invasion, and xenograft tumor growth. This population-based model supports robust phenotypic analysis of ALDH1B1 loss in colorectal cancer. For more information, contact Ascent Research.
